Telmisartan: just an antihypertensive agent? A literature review

Bibliography

• Kearney P, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. World Health Organization Press; Geneva: 2009
   Google Scholar
• Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010;105(Suppl):3-9A
   Google Scholar
• NDA 20-850 Efficacy Supplement SE1-025 Micardis® (telmisartan) tablets. Available from: www.FDA.gov [Last accessed June 2011]
   Google Scholar
• European Medicines Agency. Summary of product characteristics, Micardis®. (Micardis 20 mg, 40 mg and 80 mg tablets: summary of product characteristics. Limited BI; Bracknell, UK: 2009
   Google Scholar
• Yusuf S, Teo K, Pogue J, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83
   PubMed Web of Science ®Google Scholar
• Diener H, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes trial (PRoFESS). Cerebrovasc Dis 2007;23:368-80
   PubMed Web of Science ®Google Scholar
• Chobanian A, Bakris G, Black H. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Mancia G, Backer GD, Dominiczak A, 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007;25:1751-62
   PubMed Web of Science ®Google Scholar
• Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13:S9-20
   PubMed Web of Science ®Google Scholar
• Lifton R, Gharavi A, Geller D. Molecular mechanisms of human hypertension. Cell 2001;104:545-56
   PubMed Web of Science ®Google Scholar
• Ferrario C, Trask A, Jessup J. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005;289:H2281-90
   PubMed Web of Science ®Google Scholar
• Ferrario C, Chappell M, Dean R, Iyer S. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J Am Soc Nephrol 1998;9:1716-22
   PubMed Web of Science ®Google Scholar
• Welches W, Brosnihan K, Ferrario C. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993;52:1461-80
   PubMed Web of Science ®Google Scholar
• Santos R, Silva ASE, Maric C, Silva D. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258-63
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, Dick L. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-43
   PubMed Web of Science ®Google Scholar
• Nagata S, Kato J, Sasaki K, Minamino N. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 2006;350:1026-31
   PubMed Web of Science ®Google Scholar
• Jessup J, Trask A, Chappell M, Nagata S. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 2008;294:H2614-18
   PubMed Web of Science ®Google Scholar
• Ferrario C, Varagic J, Habibi J, Nagata S. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 2009;296:H1184-92
   Google Scholar
• Trask A, Jessup J, Chappell M, Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 2008;294:H2242-7
   Google Scholar
• Prosser H, Forster M, Richards A, Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res 2009;82:40-50
   Google Scholar
• Chrysant S, Murray A, Hoppe Y, Dattani D. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008;24:1039-47
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows S, Patel S, Fang H. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9
   PubMed Web of Science ®Google Scholar
• Yarows S, Oparil S, Patel S, Fang H. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008;25:1288-302
   PubMed Web of Science ®Google Scholar
• Cohn J, Tognoni G; Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Swedberg K, Granger C, Held P. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux R, Kjeldsen S, Julius S. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Deppe S, Boger R, Weiss J, Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2010;6:863-71
   PubMed Web of Science ®Google Scholar
• Galzerano D, Capogrosso C, Michele SD, Galzerano A. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010;6:113-33
   PubMedGoogle Scholar
• Frampton J. Telmisartan: a review of its use in cardiovascular disease prevention. Drugs 2011;71:651-77
   Google Scholar
• Battershill A, Scott L. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66:51-83
   PubMed Web of Science ®Google Scholar
• Clasen R, Schupp M, Foryst-Ludwig A, Sprang C. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005;46:137-43
   PubMed Web of Science ®Google Scholar
• Benson S, Pershadsingh H, Ho C, Chittiboyina A. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002
   PubMed Web of Science ®Google Scholar
• Marketou M, Kontaraki J, Tsakountakis N, Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am J Cardiol 2011;107:59-63
   PubMed Web of Science ®Google Scholar
• Bichu P, Nistala R, Khan A, Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009;5:129-40
   PubMedGoogle Scholar
• European Medicines Agency. Scientific discussion, Micardis®, 2005
   Google Scholar
• Ebner T, Heinzel G, Prox A, Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 1999;27:1143-9
   PubMed Web of Science ®Google Scholar
• Burnier M, Brunner H. Angiotensin II receptor antagonists. Lancet 2000;355:637-45
   PubMed Web of Science ®Google Scholar
• Wienen W, Entzeroth M, Meel J, A review on telmisartan:a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000;18:127-56
   Google Scholar
• Hunyady L, Catt K. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006;20:953-70
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, Dyal L, Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009;151:1-10. W1-2
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener H, Sacco R, Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37
   PubMed Web of Science ®Google Scholar
• Calvo C, Hermida R, Ayala D, Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22:837-46
   PubMed Web of Science ®Google Scholar
• Nishimura T, Hashimoto J, Ohkubo T, Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005;27:477-89
   PubMed Web of Science ®Google Scholar
• Zheng Z, Lin S, Shi H. A systematic review and meta-analysisof telmisartan vs valsartan in themanagement of essential hypertension. J Clin Hypertens 2010;12:414-21
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Neutel J, Davidai G, A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderatehypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006;19:104-12
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Krzesinski J, White W, Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9:203-10
   PubMed Web of Science ®Google Scholar
• Williams B, Gosse P, Lowe L, The prospective, randomized investigationof the safety and efficacy of telmisartan versus ramipril using ambulatoryblood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200
   PubMed Web of Science ®Google Scholar
• White W, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17:347-53
   PubMed Web of Science ®Google Scholar
• Smith D, Cramer M, Neutel J, Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003;8:111-17
   PubMed Web of Science ®Google Scholar
• Maillon J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-64
   Google Scholar
• Fogari R, Zoppi A, Mugellini A, Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Curr Ther Res 2008;69:1-15
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Nalbantgil I, Nalbantgil S, Ozerkan F, Yilmaz H. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004;145:50-4
   Google Scholar
• Ragot S, Ezzaher A, Meunier A, Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002;16:865-73
   PubMed Web of Science ®Google Scholar
• Stergiou G, Efstathiou S, Roussias L, Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42:491-6
   PubMed Web of Science ®Google Scholar
• Neutel J, Frishman W, Oparil S, Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999;6:161-6
   PubMedGoogle Scholar
• Freytag F, Schelling A, Meinicke T, Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild-to-moderate hypertension: a randomized, multicenter study. Clin Ther 2001;23:108-23
   PubMed Web of Science ®Google Scholar
• Galzerano D, Tammaro P, Viscovo LD, Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005;18:1563-9
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Lenis J, Orchard R, A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998;3:295-302
   PubMedGoogle Scholar
• Derosa G, Cicero A, Bertone G, Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004;26:1228-36
   PubMed Web of Science ®Google Scholar
• McGill J, Reilly P. Telmisartan plus hydrochlorothiazide versustelmisartan or hydrochlorothiazide monotherapy in patients with mildto moderate hypertension: a multicenter, randomized, double-blind,placebo-controlled, parallel-group trial. Clin Ther 2001;23:833-50
   PubMed Web of Science ®Google Scholar
• Arif A, Kadam G, Joshi C. Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. J Indian Med Assoc 2009;107:730-3
   Google Scholar
• White W, Littlejohn T, Majul C, Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010;15:205-12
   PubMed Web of Science ®Google Scholar
• Moen M. Telmisartan/amlodipine: single-pill combination in hypertension. Am J Cardiovasc Drugs 2010;10:401-12
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Sleight P, Mancia G; for the ONTARGET/TRANSCEND investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. Circulation 2009;120:1380-9
   PubMed Web of Science ®Google Scholar
• Jung A, Kim W, Park S, The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009;39:180-4
   PubMedGoogle Scholar
• Cice G, Benedetto AD, D'Isa S, Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure. A double-blind, placebo-controlled trial. J Am Coll Cardiol 2010;56:1701-8
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Brewster U, Perazella M. Renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-72
   PubMed Web of Science ®Google Scholar
• Wolf G. Angiotensin as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000;15:61-3
   PubMed Web of Science ®Google Scholar
• Weber M. The telmisartan programme of research to show telmisartan end-organ protection (PROTECTION) Programme. J Hypertens 2003;21:S37-46
   PubMed Web of Science ®Google Scholar
• Schmieder R, Delles C, Mimran A, Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007;30:1351-17
   Google Scholar
• Makino H, Haneda M, Babazono T; for the INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577-8
   PubMed Web of Science ®Google Scholar
• Barnett A, Bain S, Bouter P, Karlberg B. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61
   PubMed Web of Science ®Google Scholar
• Barnett A. Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalapril (DETAIL) study. Acta Diabetol 2005;42:S42-9
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker L, Clarke W, Berl T. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Brenner B, Cooper M, Zeeuw D, Keane W. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Parving H, Lehnert H, Rochner-Mortensen J, The effect of irbesartan on the devolopment of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Bakris G, Burgess E, Weir M, Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74:364-9
   PubMed Web of Science ®Google Scholar
• Galle J, Schwedhelm E, Pinnetti S, Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23:3174-83
   PubMed Web of Science ®Google Scholar
• Murray C, Lopez A. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42
   PubMed Web of Science ®Google Scholar
• Blood pressure lowering treatment trialists' collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Jha P, Montague T. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;359:1033-41
   Google Scholar
• Schrader J, Luders S, Kulschewski A, Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-703
   PubMed Web of Science ®Google Scholar
• Benndorf R, Appel D, Maas R, Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:367-71
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Yamada J, Koji Y, Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens 2007;20:1305-11
   PubMed Web of Science ®Google Scholar
• Bian C, Wu Y, Chen P. Telmisartan increases the permeability of endothelial cells through zonula occludens-1. Biol Pharm Bull 2009;32:416-20
   Google Scholar
• Devereux R, Koren M, Simone G, Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 1993;14(Suppl D):8-15
   Google Scholar
• Wachtell K, Lehto M, Gerdts E, Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19
   PubMed Web of Science ®Google Scholar
• Schmieder R, Kjeldsen S, Julius S, Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-11
   PubMed Web of Science ®Google Scholar
• Ducharme A, Swedberg K, Pfeffer M, Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92
   PubMed Web of Science ®Google Scholar
• Maggioni A, Latini R, Carson P, Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-57
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A, Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther. 18 Feb 2011. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Galzerano D, Caselli S, Breglio R, A multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypertensive patients. Circulation 2007;116(Suppl 2):556-7
   Google Scholar
• Lloyd-Jones D, Adams R, Brown T, Heart disease and stroke statistics – 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2010;121:e46-215
   PubMed Web of Science ®Google Scholar
• Jugdutt B. Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail Rev 2010;15:401-5
   Google Scholar
• Goldberg R, McCormick D, Gurwitz J, Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975–1995). Am J Cardiol 1998;82:1311-17
   PubMed Web of Science ®Google Scholar
• Calhoun D, Jones D, Textor S, Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabets mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
   PubMed Web of Science ®Google Scholar
• Saitoh Y, Hongwei W, Ueno H, Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab 2009;35:392-7
   Google Scholar
• Vitale C, Mercuro G, Castiglioni C, Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol May 2005;4:6
   PubMed Web of Science ®Google Scholar
• Karlberg B, Lins L, Hermansson K. TEES Study Group. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999;17:293-302
   PubMed Web of Science ®Google Scholar
• Nakayama T, Masubuchi Y, Kawauchi K, Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. Prostaglandins Leukot Essent Fatty Acids 2007;309:3-4
   Google Scholar
• Asmar R, Gosse P, Topouchian J, Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2002;3:176-80
   PubMed Web of Science ®Google Scholar
• Formosa V, Bellomo A, Iori A, The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly. Arch Gerontol Geriatr 2009;49(Suppl 1):95-101
   Google Scholar
• McCrindle B. Assessment and management of hypertension in children and adolescents. Nat Rev Cardiol 2010;7:155-63
   PubMed Web of Science ®Google Scholar
• Ostchega Y, Carroll M, Prineas R, Trends of elevated blood pressure among children and adolescents: data from the National Health and Nutrition Examination Survey 1988–2006. Am J Hypertens 2009;22:59-67
   PubMed Web of Science ®Google Scholar
• Gruskin A, Dabbagh S, Fleischmann L, Atiyeh B. Application since 1980 of antihypertensive agents to treat pediatric disease. J Hum Hypertens 1994;8:381-8
   Google Scholar
• Flynn J. Pediatric use of antihypertensive medications: much more to learn. Curr Ther Res Clin Exp 2001;62:314-28
   Web of Science ®Google Scholar
• Wells T. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. Clin Pediatr (Phila) 2010;49:938-46
   Google Scholar
• Nahata M, Holas C, Chiu Y, A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin-clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 – 8 years. Clin Ther 2005;27:1950-60
   Google Scholar
• Nevins T. ‘Why do they do that?’ The compliance conundrum. Pediatr Nephrol 2005;20:845-8
   Google Scholar
• Meier C, Simonetti G, Ghiglia S, Palatability of angiotensin II antagonists among nephropathic children. Br J Clin Pharmacol 2007;63:628-31
   Google Scholar
• Picard F, Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr 2002;22:167-97
   PubMed Web of Science ®Google Scholar
• Wakino S, Law R, Hsueh W. Vascular protective effects by activation of nuclear receptor PPAR gamma. J Diabetes Complications 2002;16:46-9
   Google Scholar
• Schiffrin E, Amiri F, Benkirane K, Peroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertension. Hypertension 2003;42:664-8
   PubMedGoogle Scholar
• Nesto R, Bell D, Bonow R, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63
   PubMed Web of Science ®Google Scholar
• Scalera F, Martens-Lobenhoffer J, Bukowska A, Effect of telmisartan on nitric oxide -asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 2008;51:696-703
   PubMed Web of Science ®Google Scholar
• Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E. Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol 2009;50:105-18
   PubMed Web of Science ®Google Scholar
• Richter A, Gondek K, Ostrowski C, Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs. Manag Care Interface 2001;14:61-9
   PubMedGoogle Scholar
• Dzau VJ, Antman EM, Black HR, The cardiovascular disease continuum validated: clinical evidence of improve patient outcomes: Part I: pathophysiology and clinical trial evidence (risk factors trough stable coronary artery disease). Circulation 2006;114:2850-70
   PubMed Web of Science ®Google Scholar
• Munger M. Use of angiotensin receptor blockers in cardiovascular protection. current evidence and future directions. Pharm Ther 2011;36:22-40
   Google Scholar
• Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008;4:67-73
   PubMedGoogle Scholar
• Comparison of effects of telmisartan and valsartan on neointima volume in diabetes. Available from: http://clinicaltrials.gov/ct2/show/NCT00599885?term=Comparison+of+effects+of+telmisartan+and+valsartan+on+neointima+volume+in+diabetes&rank=1 [Last accessed 6 May 2011]
   Google Scholar
• Mattioli A, Zennaro M, Bonatti S, Regression of left ventricular hypertrophy and improvement in diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004;97:383-8
   PubMed Web of Science ®Google Scholar
• Bahadir O, Uzunlulu M, Oguz A, Bahadir M. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007;30:49-53
   PubMed Web of Science ®Google Scholar
• Benndorf R, Rudolph T, Appel D, Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006;55:1159-64
   PubMed Web of Science ®Google Scholar
• Derosa G, Fogari E, D'Angelo A, Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007;32:261-8
   PubMed Web of Science ®Google Scholar
• Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007;46:1331-6
   PubMed Web of Science ®Google Scholar
• Koulouris S, Symeonides P, Triantafyllou K, Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidised low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005;95:1386-8
   PubMed Web of Science ®Google Scholar
• Yano Y, Hoshide S, Ishikawa J, The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 2007;20:565-72
   PubMed Web of Science ®Google Scholar
• Wago T, Yoshimoto T, Akasa I, Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res 2010;33:796-801
   PubMed Web of Science ®Google Scholar
• Kinouchi K, Ichihara A, Sakoda M, Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press Res 2010;33:304-12
   PubMedGoogle Scholar
• Brody R, Peleg E, Grossman E, Sharabi Y. Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs. Am J Hypertens 2009;22(10):1126-9
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kawachi K, Saito Y, Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J 2009;50:501-12
   PubMed Web of Science ®Google Scholar